Core Laboratories (CLB) Misses Q3 EPS by 3c, provides guidance

Core Laboratories (NYSE: CLB) reported Q3 EPS of $0.25, $0.03 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $134.4 million versus the consensus estimate of $139.66 million.

GUIDANCE:

Core Laboratories sees Q4 2024 EPS of $0.20-$0.25, versus the consensus of $0.24. Core Laboratories sees Q4 2024 revenue of $128.5-135.5 million, versus the consensus of $134 million.

For earnings history and earnings-related data on Core Laboratories (CLB) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• TechCreate Group faces NYSE American delisting proceedings
• Battery X Metals adds auto industry advisor to board